February’s Top Pharma News & Developments

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.


AstraZeneca entered agreement with TerSera Therapeutics for Zoladex


AstraZeneca entered an agreement with TerSera Therapeutics LLC for the commercial rights to Zoladex in the US and Canada. Zoladex is used to treat prostate cancer, breast cancer and several benign gynaecological disorders.

Under the agreement, TerSera is set to pay AstraZeneca USD 250 million upfront, plus USD 70 million in sales-related milestones and a quarterly share of sales in the “mid-teen percentage” range. AstraZeneca will also develop and supply Zoladex to TerSera.


Novo Nordisk filed for regulatory approval of semaglutide for the treatment of type 2 diabetes in Japan


Novo Nordisk has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for semaglutide, a new glucagon-like peptide-1 analogue for the treatment of adults with type 2 diabetes.

This move follows the recent once-weekly semaglutide regulatory submissions to the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada and SwissMedic.


Allergan Launched See America


Allergan launched a new initiative dubbed See America, through which it aims to make vision health a priority for all US residents. Increasing awareness of the diseases that can cause blindness and enhancing access to vision care for those who need it most are the initiative’s main focus.

The launch followed the release of a report published by the National Academies of Sciences, Engineering, and Medicine (NASEM), which stressed upon the overwhelming number of Americans affected by blindness from preventable causes.


Amgen’s Parsabiv got FDA approval


The US Food and Drug Administration (FDA) approved Amgen’s Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis.

Parsabiv is the first therapy approved for this condition in 12 years. It is also the only calcimimetic that can be administered intravenously three times a week after the hemodialysis session.


Roche to start second late-stage study of Alzheimer’s disease drug


Roche’s partner AC Immune revealed that Roche is set to launch a second Phase III study of the experimental Alzheimer’s disease therapy crenezumab. The latter was discovered by AC Immune and out-licensed to Roche’s Genentech unit in 2006. The CREAD2 trial will enrol 750 patients with prodromal or mild Alzheimer’s disease.


Boehringer Ingelheim’s Giotrif got approved for lung cancer in China


Global pharmaceutical company Boehringer Ingelheim announced that their afatinib (Giotrif), an irreversible second-generation ErbB family blocker, was approved for lung cancer in China.

Afatinib has received Imported Drugs License (IDL) status by the China Food and Drug Administration (CFDA) for locally advanced or metastatic EGFR mutation-positive lung cancer patients who have not received any prior therapy with tyrosine kinase inhibitors, as well as for patients with locally advanced or metastatic squamous cell carcinoma of the lung whose disease has progressed on or after treatment with platinum-based chemotherapy.

Afatinib is the first and only second-generation ErbB family blocker approved in China.


Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are:

  • EHA 2017 – 445 rooms in fourteen 4-star hotels
  • ESMO 2017 – 440 rooms in ten 4-star hotels
  • ESC 2017 – 150 rooms in five 4-star hotels
  • EURETINA 2017 – 160 rooms in five 4-star hotels
  • EASD 2017 – 423 rooms in thirteen 4-star hotels
  • EAACI 2017 – 688 rooms in fourteen 4-star hotels

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s